Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Tyra Biosciences, Inc. (TYRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-04
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Tyra Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-22 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-03 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |